BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/11/2014 9:21:00 AM | Browse: 374 | Download: 288
Publication Name World Journal of Nephrology
Manuscript ID 3858
Country/Territory
Received
2013-05-29 08:19
Peer-Review Started
2013-05-29 18:42
To Make the First Decision
2013-07-19 08:24
Return for Revision
2013-07-22 13:48
Revised
2013-08-02 14:48
Second Decision
2013-08-29 07:55
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-08-29 09:59
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2013-10-23 19:02
Publish the Manuscript Online
2013-11-04 12:41
ISSN 2220-6124 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Medicine, General and Internal
Manuscript Type Brief Articles
Article Title Retrospective Aliskiren and Losartan study in non-diabetic chronic kidney disease
Manuscript Source
All Author List Keng-Thye Woo, Hui-Lin Choong, Kok-Seng Wong, Han-Kim Tan, Marjorie Foo, Fook-Chong Stephanie, Evan JC Lee, Vathsala Anantharaman, Grace SL Lee and Choong-Meng Chan
Funding Agency and Grant Number
Corresponding author Keng-Thye Woo, Professor, Department of Renal Medicine Singapore General Hospital, Outram Road, 169608, Singapore. woo.keng.thye@sgh.com.sg
Keywords Aliskiren; Chronic kidney disease disease; Clinical trial
Core Tip The Aliskiren trial in type 2 diabetes using Cardio-Renal Endpoints (ALTITUDE) study was able to unmask serious adverse events like ischemic heart disease and strokes because it had included Cardio-Renal Endpoints among its primary end points. It may be advisable to require future trials on drugs which could impact on the kidneys, heart and brain to have similar Cardio-Renal Endpoints or Cardio-Neuro-Renal End points to further ensure therapeutic safety of the trial drug. Our modest study compared to the magnitude of the ALTITUDE study still managed to detect the problem of hyperkalaemia in the group treated with Combination therapy with Aliskiren and ARB. Based on our study it would appear that the findings of the ALTITUDE study would also apply to non-diabetic Chronic Kidney Disease patients.
Publish Date 2013-11-04 12:41
Citation Woo KT, Choong HL, Wong KS, Tan HK, Foo M, Stephanie FC, Lee EJC, Anantharaman V, Lee GSL, Chan CM. A retrospective Aliskiren and Losartan study in non-diabetic chronic kidney disease. World J Nephrol 2013; 2(4): 129-135
Url http://www.wjgnet.com/2220-6124/full/v2/i4/129.htm
DOI http://dx.doi.org/10.5527/wjn.v2.i4.129
Full Article (PDF) WJN-2-129.pdf
Manuscript File 3858-Review.docx
Answering Reviewers 3858-Answering reviewers.pdf
Copyright License Agreement 3858-Copyright assignment.pdf
Institutional Review Board Approval Form or Document Aliskiren Study IRB.pdf
Non-Native Speakers of English Editing Certificate 3858-Language certificate.pdf
Peer-review Report 3858-Peer review.pdf
Scientific Editor Work List 3858-Scientific editor work list.doc